NCT06847607View on ClinicalTrials.gov

A Multicenter Prospective Study of Iptacopan in the Treatment of Refractory/Relapsed Autoimmune Hemolytic Anemia (AIHA)

NANot yet recruitingINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

March 1, 2025

Primary Completion Date

October 30, 2025

Study Completion Date

June 30, 2026

Conditions

AIHA - Warm Autoimmune Hemolytic AnemiaAIHA - Cold Autoimmune Hemolytic Anemia

Interventions

DRUG

Iptacopan

Trial Locations (1)

Unknown

Bing Han, Beijing

All Listed Sponsors

lead

Bing Han

OTHER

NCT06847607 - A Multicenter Prospective Study of Iptacopan in the Treatment of Refractory/Relapsed Autoimmune Hemolytic Anemia (AIHA) | Biotech Hunter | Biotech Hunter